WebSacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2 -directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple … WebOct 31, 2024 · Trodelvy (sacituzumab govitecan-hziy) is a chemotherapy drug used to treat certain triple-negative breast cancers (TNBC) and urothelial cancers (a type of bladder cancer).It is used to treat patients with a poor prognosis and limited treatment options who have already been treated with other therapies and who have advanced tumors or tumors …
Financial Assistance TRODELVY® (sacituzumab govitecan-hziy)
WebSep 19, 2024 · Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy. Trodelvy is the ... WebTrodelvy FDA Approved Yes FDA label information for this drug is available at DailyMed. Use in Cancer Sacituzumab govitecan-hziy is approved to treat adults with: Breast cancer that is metastatic (has spread to other parts of the body) or … european gas cards
Sacituzumab Govitecan-hziy - NCI - National Cancer Institute
WebTRODELVY. TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use. Initial U.S. Approval: 2024. WARNING: NEUTROPENIA AND DIARRHEA See full prescribing … WebTRODELVY ® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread (metastatic) or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine. WebTrodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease (see section 5.1). european gas conference wien